Atara Biotherapeutics, Inc. (0HIY.L)
USD 10.43
(-0.02%)
USD 10.43
(-0.02%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 45.69 Million USD | -21.31% |
| 2022 | 58.06 Million USD | 127.54% |
| 2021 | 25.51 Million USD | 95.68% |
| 2020 | 13.04 Million USD | -7.75% |
| 2019 | 14.13 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 36.44 Million USD | 2.46% |
| 2024 Q1 | 35.57 Million USD | 0.0% |
| 2023 Q1 | 54.91 Million USD | -5.42% |
| 2023 Q3 | 48.5 Million USD | -6.27% |
| 2023 FY | 45.69 Million USD | -21.31% |
| 2023 Q4 | 45.69 Million USD | -5.8% |
| 2023 Q2 | 51.75 Million USD | -5.76% |
| 2022 Q1 | 17.45 Million USD | -31.61% |
| 2022 Q3 | 61.07 Million USD | -4.57% |
| 2022 Q2 | 63.99 Million USD | 266.69% |
| 2022 FY | 58.06 Million USD | 127.54% |
| 2022 Q4 | 58.06 Million USD | -4.93% |
| 2021 Q2 | 12.18 Million USD | -3.08% |
| 2021 FY | 25.51 Million USD | 95.68% |
| 2021 Q1 | 12.56 Million USD | -3.62% |
| 2021 Q4 | 25.51 Million USD | 3.84% |
| 2021 Q3 | 24.57 Million USD | 101.72% |
| 2020 Q2 | 13.42 Million USD | -2.82% |
| 2020 Q4 | 13.04 Million USD | -0.67% |
| 2020 FY | 13.04 Million USD | -7.75% |
| 2020 Q3 | 13.12 Million USD | -2.17% |
| 2020 Q1 | 13.8 Million USD | -2.31% |
| 2019 Q4 | 14.13 Million USD | -2.73% |
| 2019 Q3 | 14.53 Million USD | -2.59% |
| 2019 Q2 | 14.91 Million USD | 3.34% |
| 2019 Q1 | 14.43 Million USD | 0.0% |
| 2019 FY | 14.13 Million USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | -100.0% |
| 2018 Q3 | 10.3 Million USD | 0.0% |
| 2018 Q2 | 10.3 Million USD | 0.0% |
| 2018 Q1 | 10.3 Million USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 24.37 Million USD | -87.482% |
| Dynavax Technologies Corporation | 252.41 Million USD | 81.898% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -37.646% |
| Perrigo Company plc | 3.63 Billion USD | 98.742% |
| Illumina, Inc. | 1.48 Billion USD | 96.931% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.854% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -4469.3% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 99.432% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 99.647% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 73.702% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 98.309% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -94.116% |
| Waters Corporation | 2.3 Billion USD | 98.018% |
| Biogen Inc. | 7.18 Billion USD | 99.364% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -36.336% |
| Evolus, Inc. | 120.35 Million USD | 62.036% |
| Adicet Bio, Inc. | 17.7 Million USD | -158.109% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -23.231% |
| bluebird bio, Inc. | 224.41 Million USD | 79.639% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 90.89% |
| FibroGen, Inc. | 89.69 Million USD | 49.058% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 98.329% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -1310.874% |
| Homology Medicines, Inc. | 43.17 Million USD | -5.83% |
| Geron Corporation | 35.05 Million USD | -30.361% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 98.05% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 88.219% |
| Myriad Genetics, Inc. | 130.9 Million USD | 65.093% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -4781.731% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 52.771% |
| Zoetis Inc. | 6.56 Billion USD | 99.304% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -938.005% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 97.687% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 92.296% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 93.695% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -33.644% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 96.737% |
| Verastem, Inc. | 40.08 Million USD | -13.987% |
| Nektar Therapeutics | 112.62 Million USD | 59.429% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 74.34% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -1386.435% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 95.965% |
| OPKO Health, Inc. | 222.03 Million USD | 79.421% |
| Exelixis, Inc. | 189.94 Million USD | 75.944% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 82.31% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 130.06 Million USD | 64.869% |
| Imunon, Inc. | 1.13 Million USD | -3910.645% |
| Blueprint Medicines Corporation | 610.96 Million USD | 92.521% |
| Insmed Incorporated | 1.19 Billion USD | 96.171% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 96.952% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 19.82% |
| TG Therapeutics, Inc. | 100.11 Million USD | 54.361% |
| Incyte Corporation | 29.16 Million USD | -56.687% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 89.766% |